Related Experiment Video
Updated: May 23, 2025
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
10.9K
Drug evaluation: mepolizumab in chronic obstructive pulmonary disease
Matheus Rabahi1, Ian D Pavord2
1Departamento de Pneumologia, Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil.
Immunotherapy
|May 14, 2025
Summary
New biologic treatments show promise for chronic obstructive pulmonary disease (COPD) patients with type-2 airway inflammation. Further research is needed to determine efficacy in specific patient subgroups with active inflammation and minimal lung damage.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a major global health concern, characterized by persistent respiratory symptoms and exacerbations.
- COPD is a heterogeneous condition with diverse clinical presentations and underlying mechanisms.
- Current therapies, including bronchodilators and corticosteroids, offer insufficient control for many patients, highlighting an unmet need for novel treatments.
Purpose of the Study:
- To review initial clinical trial data of mepolizumab, a biologic therapy targeting interleukin-5 (IL-5), in patients with type-2 high COPD.
- To evaluate the potential of mepolizumab in a specific COPD phenotype characterized by type-2 airway inflammation.
- To propose a refined approach for assessing treatment efficacy in COPD based on disease activity and associated damage.
Main Methods:
- Review of clinical trial data for mepolizumab in patients with type-2 high COPD.
- Analysis of mepolizumab's mechanism of action, targeting IL-5 to reduce eosinophil counts.
- Stratification of patient populations based on disease severity, type-2 inflammation status, and extent of lung and extra-pulmonary damage.
Main Results:
- Mepolizumab targets IL-5, reducing blood and tissue eosinophils, a key factor in type-2 inflammation.
- Initial trials suggest modest efficacy of mepolizumab in severe COPD.
- The efficacy may be underestimated in patients with active type-2 inflammation and less severe lung/extra-pulmonary damage.
Conclusions:
- Mepolizumab represents a promising biologic treatment for COPD patients with type-2 airway inflammation.
- The effectiveness of mepolizumab may be more pronounced in patients with active type-2 inflammation and limited associated organ damage.
- Future research should focus on evaluating mepolizumab's impact on disease course in carefully selected COPD patient cohorts with high disease activity and low comorbidity burden.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
170
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
170
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
01:17Drugs Used in Lower Respiratory Disorders: Overview
333
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
333
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
211
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
211
01:22Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K